In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes

被引：1
|
作者：
Chagla, Zain [1 ]
机构：
[1] St Josephs Healthcare, Hamilton, ON, Canada
来源：
ANNALS OF INTERNAL MEDICINE | 2024年 / 177卷 / 01期
关键词：
D O I：
10.7326/J23-0108
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Source Citation Sommer I, Ledinger D, Thaler K, et al. Outpatient treatment of confirmed COVID-19: a living, rapid evidence review for the American College of Physicians (version 2). Ann Intern Med. 2023;176:1377-1385. 37722115 Clinical Impact Ratings GIM/FP/GP: Infectious Disease: Public Health:
引用
收藏
页码：JC7 / JC7
页数：1
相关论文
共 50 条
  • [1] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19
    Focosi, Daniele
    Nicastri, Emanuele
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (10)
  • [2] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
    Cheng, Franco Wing Tak
    Yan, Vincent Ka Chun
    Wan, Eric Yuk Fai
    Chui, Celine Sze Ling
    Lai, Francisco Tsz Tsun
    Wong, Carlos King Ho
    Li, Xue
    Zhang, Irene Ran
    Tang, Sydney Chi Wai
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (05): : 1244 - 1253
  • [3] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 Response
    Wan, Eric Yuk Fai
    Yan, Vincent Ka Chun
    Mok, Anna Hoi Ying
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (10) : eL230265
  • [4] Nirmatrelvir-ritonavir for COVID-19
    McDonald, Emily G.
    Lee, Todd C.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (06) : E218 - E218
  • [5] Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the Omicron era
    Faraz, Fatima
    Rehman, Mohammad Ebad Ur
    Shahid, Abia
    Ghafoor, Muhammad Saqib
    Cheema, Huzaifa Ahmad
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (11) : 1017 - 1019
  • [6] Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
    Imran, Laiba
    Zubair, Rooja
    Mughal, Sanila
    Shakeel, Ramsha
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (02): : 313 - 315
  • [7] Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase
    Wan, Eric Yuk Fai
    Wang, Boyuan
    Mathur, Sukriti
    Chan, Cheyenne I. Ying
    Yan, Vincent Ka Chun
    Lai, Francisco Tsz Tsun
    Chui, Celine Sze Ling
    Li, Xue
    Wong, Carlos King Ho
    Li, Philip Hei
    Lau, Chak Sing
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    JOURNAL OF INFECTION, 2023, 86 (06) : 622 - 625
  • [8] Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection
    Qi, Tangkai
    Jin, Yinpeng
    Wang, He
    Liao, Yixin
    Liu, Tiefu
    Mao, Enqiang
    Li, Feng
    Li, Yinchuan
    Fan, Xiaohong
    Ling, Yun
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [9] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [10] Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19
    LeBras, Marlys
    Crawley, Alex
    Legge, Marc
    Takaya, Satchan
    Lee, Stephen
    Regier, Loren
    CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : 546 - 549
12345